The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Idebenone and reduced cardiac hypertrophy in Friedreich's ataxia
Open accessAbstract
Background: Friedreich's ataxia encodes a protein of unknown function, frataxin. The loss of frataxin is caused by a large GAA trinucleotide expansion in the first intron of the gene, resulting in deficiency of a Krebs cycle enzyme, aconitase, and of three mitochondrial respiratory chain complexes (I–III). This causes oxidative stress. Idebenone, a short chain quinone acting as an antioxidant, has been shown to protect heart muscle against oxidative stress in some patients. Objective: To assess the efficiency of idebenone on cardiac hypertrophy in Friedreich's ataxia. Design: Prospective, open trial. Setting: Tertiary care centre. Methods: Idebenone (5 mg/kg/day) was given orally to 38 patients with Friedreich's ataxia aged 4–22 years (20 males, 18 females). Cardiac ultrasound indices were recorded before and after idebenone treatment. Results: After six months, cardiac ultrasound indicated a reduction in left ventricular mass of more than 20% in about half the patients (p < 0.001). The shortening fraction was initially reduced in six of the 38 patients (by between 11–26%) and it improved in five of these. In one patient, the shortening fraction only responded to 10 mg/kg/day of idebenone. No correlation was found between responsiveness to idebenone and age, sex, initial ultrasound indices, or the number of GAA repeats in the frataxin gene. Conclusions: Idebenone is effective at controlling cardiac hypertrophy in Friedreich's ataxia. As the drug has no serious side effects, there is a good case for giving it continuously in a dose of 5–10 mg/kg/day in patients with Friedreich's ataxia at the onset of hypertrophic cardiomyopathy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Friedreich's Ataxia: Autosomal Recessive Disease Caused by an Intronic GAA Triplet Repeat Expansion
Campuzano, V., Montermini, L., Moltò, M. D., Pianese, L., Cossée, M., Cavalcanti, F., Monros, E., Rodius, F., Duclos, F., Monticelli, A., et al. (1996) · Science · doi:10.1126/science.271.5254.1423 · Cited by 2,786
Clinical and Genetic Abnormalities in Patients with Friedreich's Ataxia
Dürr, A., Cossee, M., Agid, Y., Campuzano, V., Mignard, C., Penet, C., Mandel, J.-L., Brice, A., & Koenig, M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610173351601 · Cited by 1,071
Wang, J., Wilhelmsson, H., Graff, C., Li, H., Oldfors, A., Rustin, P., Brüning, J. C., Kahn, C. R., Clayton, D. A., Barsh, G. S., et al. (1999) · Nature Genetics · doi:10.1038/5089 · Cited by 435
Self-citationCossee, M. (2000) · Human Molecular Genetics · doi:10.1093/hmg/9.8.1219 · Cited by 377
Cited by
Neurodegenerative diseases and oxidative stress
Barnham, K. J., Masters, C. L., & Bush, A. I. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1330 · Cited by 3,683
Mechanisms of Diabetic Complications
Forbes, J. M., & Cooper, M. E. (2013) · Physiological Reviews · doi:10.1152/physrev.00045.2011 · Cited by 2,890
Trinucleotide Repeat Disorders
Orr, H. T., & Zoghbi, H. Y. (2007) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.29.051605.113042 · Cited by 1,368
Oxidative Stress as a Major Culprit in Kidney Disease in Diabetes
Forbes, J. M., Coughlan, M. T., & Cooper, M. E. (2008) · Diabetes · doi:10.2337/db08-0057 · Cited by 1,203
“Studies in humans with Friedreich’s ataxia suggest that this antioxidant is a safe and highly efficient way to protect mitochondrial function from oxidative damage (18).”
BackgroundSchapira, A. H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68970-8 · Cited by 591
Zeviani, M., & Spinazzola, A. (2003) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-003-0026-9 · Cited by 533
Oxidative stress, mitochondrial dysfunction and cellular stress response in Friedreich's ataxia
Calabrese, V., Lodi, R., Tonon, C., D'Agata, V., Sapienza, M., Scapagnini, G., Mangiameli, A., Pennisi, G., Stella, A. M. G., & Butterfield, D. A. (2005) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2005.03.012 · Cited by 406
AGE, RAGE, and ROS in Diabetic Nephropathy
Tan, A. L. Y., Forbes, J. M., & Cooper, M. E. (2007) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2007.01.006 · Cited by 368
Jauslin, M. L., Meier, T., Smith, R. A. J., & Murphy, P. M. (2003) · The FASEB Journal · doi:10.1096/fj.03-0240fje · Cited by 358
James, A. M., Cochemé, H. M., Smith, R. A. J., & Murphy, M. P. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501527200 · Cited by 353
Di Prospero, N. A., Baker, A., Jeffries, N., & Fischbeck, K. H. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70220-x · Cited by 300
Molecular Strategies for Targeting Antioxidants to Mitochondria: Therapeutic Implications
Apostolova, N., & Victor, V. M. (2015) · Antioxidants & Redox Signaling · doi:10.1089/ars.2014.5952 · Cited by 299
Clinical features and molecular genetics of autosomal recessive cerebellar ataxias
Fogel, B. L., & Perlman, S. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70054-6 · Cited by 290
Beal, M. F. (2004) · Journal of Bioenergetics and Biomembranes · doi:10.1023/b:jobb.0000041772.74810.92 · Cited by 277
Calabrese, V., Cornelius, C., Mancuso, C., Pennisi, G., Calafato, S., Bellia, F., Bates, T. E., Giuffrida Stella, A. M., Schapira, T., Dinkova Kostova, A. T., et al. (2008) · Neurochemical Research · doi:10.1007/s11064-008-9775-9 · Cited by 268
Diagnosis and treatment of Friedreich ataxia: a European perspective
Schulz, J. B., Boesch, S., Bürk, K., Dürr, A., Giunti, P., Mariotti, C., Pousset, F., Schöls, L., Vankan, P., & Pandolfo, M. (2009) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.26 · Cited by 258
Bioenergetic approaches for neuroprotection in Parkinson's disease
Beal, M. F. (2003) · Annals of Neurology · doi:10.1002/ana.10479 · Cited by 236
Mitochondrial Medicine for Aging and Neurodegenerative Diseases
Reddy, P. H. (2008) · NeuroMolecular Medicine · doi:10.1007/s12017-008-8044-z · Cited by 230
“The role of oxidative damage in FRDA is supported by studies of FRDA patients in which the antioxidant idebenone was found to reduce myocardial hypertrophy and to decrease markers of oxidative stress (Hausse et al. 2002; Schultz et al. 2000).”
BackgroundFriedreich ataxia: the oxidative stress paradox
Seznec, H., Simon, D., Bouton, C., Reutenauer, L., Hertzog, A., Golik, P., Procaccio, V., Patel, M., Drapier, J.-C., Koenig, M., et al. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi042 · Cited by 219
The role of mitochondria in inherited neurodegenerative diseases
Kwong, J. Q., Beal, M. F., & Manfredi, G. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03990.x · Cited by 180
Seznec, H. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh114 · Cited by 138
Iron and iron-responsive proteins in the cardiomyopathy of Friedreich's ataxia
Michael, S., Petrocine, S. V., Qian, J., Lamarche, J. B., Knutson, M. D., Garrick, M. D., & Koeppen, A. H. (2006) · The Cerebellum · doi:10.1080/14734220600913246 · Cited by 122
“If chelators are to be used, they must be able to enter the mitochondrial interior (48), and the combined administration of a chelating drug, an anti-inflammatory medication, and idebenone (49) may be beneficial.”
BackgroundPharmacological treatments for Friedreich ataxia
Kearney, M., Orrell, R. W., Fahey, M., Brassington, R., & Pandolfo, M. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007791.pub4 · Cited by 74
Molecular insights into Friedreich's ataxia and antioxidant-based therapies
Rötig, A., Sidi, D., Munnich, A., & Rustin, P. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(02)02330-4 · Cited by 46
Self-citationFrataxin and frataxin deficiency in Friedreich's ataxia
Wilson, R. B. (2003) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(02)00432-x · Cited by 32
Miranda, C. J., Santos, M. M., Ohshima, K., Tessaro, M., Sequeiros, J., & Pandolfo, M. (2004) · FEBS Letters · doi:10.1016/j.febslet.2004.07.022 · Cited by 30
Metadata
- Authors
- Hausse, A. O., Aggoun, Y., Bonnet, D., Sidi, D., Munnich, A., Rötig, A., & Rustin, P.
- Venue
- Heart
- Publisher
- BMJ
- Published
- 2002-04
- Volume
- 87
- Issue
- 4
- Pages
- 346-349
- ISSN
- 1355-6037 (ISSN-L)
- 1468-201X
- OpenAlex
- W2160750657
- Cited by
- 252
- References
- 4
- FWCI
- 6.18
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.